Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis.

Eslam Mohammed RabeaMohamed Mohamed BelalAbdelrahman H HafezAshraf Hassan ElbannaMahmoud Ahmed KhalifaAnas Zakarya NoureldenNada H MahmoudMohamed Sayed Zaazouee

Published in: Acta neurologica Belgica (2024)

In summary, our meta-analysis indicates that natalizumab maintains its effectiveness under extended interval dosing [up to 8 weeks], presenting comparable risks for clinical relapses, MRI lesions, EDSS, and PML. Caution is advised given study limitations and heterogeneity. Robust conclusions necessitate well-designed high-quality prospective studies.

Keyphrases

multiple sclerosis
systematic review
end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
magnetic resonance imaging
white matter
case control
peritoneal dialysis
single cell
meta analyses
computed tomography
patient reported
preterm birth